Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers (PDF 9.5 MB)

  Published:

  04 October 2017

• Final appraisal determination committee papers (PDF 5.13 MB)

  Published:

  04 October 2017